| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 148 | 2026 | 1712 | 10.780 |
Why?
|
| Immunotherapy, Adoptive | 104 | 2026 | 873 | 9.460 |
Why?
|
| Receptors, Antigen, T-Cell | 52 | 2024 | 458 | 7.160 |
Why?
|
| Genetic Therapy | 77 | 2024 | 683 | 6.860 |
Why?
|
| T-Lymphocytes, Cytotoxic | 90 | 2024 | 512 | 5.870 |
Why?
|
| Gene Transfer Techniques | 59 | 2015 | 336 | 4.930 |
Why?
|
| Bone Marrow Transplantation | 106 | 2014 | 574 | 4.640 |
Why?
|
| Genetic Vectors | 78 | 2022 | 891 | 4.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 66 | 2023 | 1168 | 4.090 |
Why?
|
| Caspase 9 | 15 | 2016 | 75 | 3.960 |
Why?
|
| Neoplasms | 56 | 2024 | 2857 | 3.400 |
Why?
|
| Interleukin-2 | 43 | 2015 | 236 | 3.360 |
Why?
|
| Immunotherapy | 43 | 2025 | 742 | 3.240 |
Why?
|
| Adenoviridae | 45 | 2023 | 573 | 3.190 |
Why?
|
| Herpesvirus 4, Human | 78 | 2024 | 615 | 3.170 |
Why?
|
| Recombinant Fusion Proteins | 31 | 2018 | 680 | 2.840 |
Why?
|
| Neuroblastoma | 31 | 2017 | 539 | 2.760 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 23 | 2021 | 167 | 2.720 |
Why?
|
| Antigens, Neoplasm | 30 | 2026 | 399 | 2.540 |
Why?
|
| Graft vs Host Disease | 44 | 2021 | 632 | 2.340 |
Why?
|
| Genes, Transgenic, Suicide | 13 | 2016 | 47 | 2.320 |
Why?
|
| Cancer Vaccines | 19 | 2016 | 188 | 2.230 |
Why?
|
| Cell- and Tissue-Based Therapy | 13 | 2023 | 143 | 2.210 |
Why?
|
| CD40 Ligand | 15 | 2011 | 63 | 2.110 |
Why?
|
| Antibodies, Monoclonal | 37 | 2021 | 989 | 2.030 |
Why?
|
| Leukemia, Myeloid, Acute | 28 | 2021 | 549 | 1.890 |
Why?
|
| Hematopoietic Stem Cells | 38 | 2007 | 518 | 1.840 |
Why?
|
| Genetic Markers | 35 | 2007 | 599 | 1.780 |
Why?
|
| Stem Cell Transplantation | 19 | 2020 | 231 | 1.740 |
Why?
|
| Transgenes | 21 | 2018 | 330 | 1.700 |
Why?
|
| Retroviridae | 34 | 2022 | 182 | 1.700 |
Why?
|
| Hematologic Neoplasms | 17 | 2024 | 294 | 1.670 |
Why?
|
| Humans | 466 | 2026 | 127511 | 1.640 |
Why?
|
| Lymphocyte Activation | 51 | 2021 | 672 | 1.630 |
Why?
|
| Hodgkin Disease | 26 | 2020 | 305 | 1.540 |
Why?
|
| Adoptive Transfer | 22 | 2016 | 228 | 1.530 |
Why?
|
| Leukemia | 31 | 2018 | 356 | 1.510 |
Why?
|
| Transduction, Genetic | 33 | 2017 | 283 | 1.500 |
Why?
|
| Lymphocyte Depletion | 24 | 2024 | 120 | 1.490 |
Why?
|
| Oncolytic Virotherapy | 8 | 2023 | 89 | 1.480 |
Why?
|
| Cytotoxicity, Immunologic | 31 | 2024 | 258 | 1.450 |
Why?
|
| Genetic Engineering | 11 | 2018 | 159 | 1.390 |
Why?
|
| Transplantation Conditioning | 18 | 2019 | 304 | 1.320 |
Why?
|
| Cell Engineering | 5 | 2020 | 19 | 1.300 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2022 | 90 | 1.290 |
Why?
|
| Lymphoma | 20 | 2023 | 319 | 1.260 |
Why?
|
| Transplantation, Homologous | 47 | 2021 | 642 | 1.260 |
Why?
|
| Gene Expression | 21 | 2017 | 1487 | 1.240 |
Why?
|
| Antigens, CD19 | 21 | 2024 | 171 | 1.240 |
Why?
|
| Epstein-Barr Virus Infections | 24 | 2024 | 273 | 1.220 |
Why?
|
| Apoptosis | 17 | 2024 | 1823 | 1.220 |
Why?
|
| Antigens, CD | 16 | 2015 | 415 | 1.120 |
Why?
|
| Animals | 124 | 2024 | 33208 | 1.120 |
Why?
|
| Killer Cells, Natural | 23 | 2023 | 333 | 1.110 |
Why?
|
| Interleukin-12 | 10 | 2021 | 124 | 1.100 |
Why?
|
| Periodicals as Topic | 4 | 2014 | 180 | 1.090 |
Why?
|
| Pancreatic Neoplasms | 6 | 2026 | 713 | 1.080 |
Why?
|
| Xenograft Model Antitumor Assays | 23 | 2024 | 947 | 1.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2026 | 165 | 1.030 |
Why?
|
| Leukocyte Common Antigens | 10 | 2023 | 83 | 1.020 |
Why?
|
| Cell Line, Tumor | 41 | 2024 | 3503 | 1.000 |
Why?
|
| CD5 Antigens | 7 | 2024 | 33 | 0.980 |
Why?
|
| Oncolytic Viruses | 6 | 2024 | 75 | 0.980 |
Why?
|
| Transplantation, Autologous | 34 | 2020 | 265 | 0.930 |
Why?
|
| Lymphoproliferative Disorders | 16 | 2015 | 217 | 0.870 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2019 | 152 | 0.870 |
Why?
|
| Virus Diseases | 10 | 2020 | 271 | 0.850 |
Why?
|
| Virus Replication | 9 | 2022 | 593 | 0.830 |
Why?
|
| Gangliosides | 5 | 2024 | 67 | 0.820 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2014 | 199 | 0.820 |
Why?
|
| Mice | 78 | 2024 | 17693 | 0.810 |
Why?
|
| Cytokines | 27 | 2023 | 1326 | 0.810 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2020 | 638 | 0.800 |
Why?
|
| B-Lymphocytes | 33 | 2013 | 516 | 0.800 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2015 | 210 | 0.790 |
Why?
|
| Flow Cytometry | 22 | 2016 | 755 | 0.790 |
Why?
|
| Musa | 1 | 2023 | 6 | 0.780 |
Why?
|
| Dendritic Cells | 18 | 2010 | 435 | 0.780 |
Why?
|
| Tumor Escape | 8 | 2018 | 62 | 0.770 |
Why?
|
| Lymphoma, B-Cell | 9 | 2019 | 138 | 0.770 |
Why?
|
| Combined Modality Therapy | 18 | 2024 | 1235 | 0.760 |
Why?
|
| Publishing | 3 | 2014 | 104 | 0.760 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2024 | 26 | 0.730 |
Why?
|
| CD8-Positive T-Lymphocytes | 15 | 2020 | 439 | 0.720 |
Why?
|
| Leukemia, Myeloid | 14 | 2006 | 79 | 0.710 |
Why?
|
| Male | 145 | 2026 | 62895 | 0.700 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 627 | 0.690 |
Why?
|
| Neoplastic Stem Cells | 10 | 2011 | 329 | 0.680 |
Why?
|
| Female | 144 | 2026 | 68770 | 0.680 |
Why?
|
| Interferon-gamma | 21 | 2013 | 528 | 0.670 |
Why?
|
| Helper Viruses | 1 | 2021 | 45 | 0.670 |
Why?
|
| Cytomegalovirus | 20 | 2017 | 258 | 0.670 |
Why?
|
| Child | 108 | 2024 | 25298 | 0.670 |
Why?
|
| Adolescent | 97 | 2024 | 20156 | 0.660 |
Why?
|
| Cell Proliferation | 26 | 2018 | 2400 | 0.650 |
Why?
|
| Graft vs Leukemia Effect | 4 | 2021 | 36 | 0.650 |
Why?
|
| Tumor Cells, Cultured | 33 | 2008 | 984 | 0.650 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2019 | 790 | 0.630 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 1494 | 0.630 |
Why?
|
| CD4-Positive T-Lymphocytes | 16 | 2020 | 479 | 0.630 |
Why?
|
| Lymphocyte Transfusion | 7 | 2021 | 57 | 0.620 |
Why?
|
| Child, Preschool | 71 | 2024 | 14463 | 0.620 |
Why?
|
| Dependovirus | 1 | 2021 | 144 | 0.620 |
Why?
|
| Autoimmune Diseases | 7 | 2018 | 270 | 0.620 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2024 | 1239 | 0.610 |
Why?
|
| Treatment Outcome | 51 | 2026 | 12582 | 0.610 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2017 | 133 | 0.610 |
Why?
|
| Membrane Glycoproteins | 7 | 2005 | 416 | 0.600 |
Why?
|
| Antibody Formation | 12 | 2009 | 267 | 0.600 |
Why?
|
| Interleukin-15 | 6 | 2024 | 100 | 0.600 |
Why?
|
| Medical Oncology | 4 | 2018 | 229 | 0.600 |
Why?
|
| Molecular Targeted Therapy | 4 | 2017 | 380 | 0.570 |
Why?
|
| Viruses | 2 | 2016 | 114 | 0.570 |
Why?
|
| Antibodies, Neoplasm | 10 | 2017 | 56 | 0.570 |
Why?
|
| Multiple Myeloma | 10 | 2020 | 209 | 0.560 |
Why?
|
| Bone Marrow Cells | 20 | 2007 | 240 | 0.550 |
Why?
|
| Lymphocytes | 17 | 2023 | 355 | 0.550 |
Why?
|
| Recurrence | 28 | 2021 | 1422 | 0.550 |
Why?
|
| Antineoplastic Agents | 21 | 2017 | 1759 | 0.550 |
Why?
|
| Coculture Techniques | 15 | 2021 | 230 | 0.540 |
Why?
|
| Transfection | 17 | 2012 | 948 | 0.540 |
Why?
|
| Leukemia, Hairy Cell | 8 | 1993 | 16 | 0.540 |
Why?
|
| Adult | 98 | 2026 | 30609 | 0.530 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2014 | 219 | 0.520 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 68 | 0.520 |
Why?
|
| Antibodies, Bispecific | 3 | 2024 | 50 | 0.520 |
Why?
|
| Immunophenotyping | 26 | 2023 | 330 | 0.520 |
Why?
|
| Mice, SCID | 20 | 2021 | 570 | 0.510 |
Why?
|
| Cells, Cultured | 32 | 2020 | 2901 | 0.500 |
Why?
|
| Lymphocyte Subsets | 4 | 2017 | 39 | 0.500 |
Why?
|
| Lymphokines | 7 | 2007 | 64 | 0.490 |
Why?
|
| Lymphoma, T-Cell | 4 | 2024 | 61 | 0.490 |
Why?
|
| Tissue Donors | 16 | 2021 | 506 | 0.490 |
Why?
|
| Cell Line | 29 | 2022 | 2565 | 0.480 |
Why?
|
| Cell Survival | 16 | 2018 | 840 | 0.470 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 124 | 0.470 |
Why?
|
| Genes, Reporter | 8 | 2015 | 346 | 0.470 |
Why?
|
| Viral Matrix Proteins | 11 | 2018 | 107 | 0.470 |
Why?
|
| CD28 Antigens | 7 | 2024 | 74 | 0.470 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 5 | 2021 | 72 | 0.460 |
Why?
|
| Middle Aged | 62 | 2026 | 27894 | 0.460 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 316 | 0.440 |
Why?
|
| Bone Neoplasms | 4 | 2015 | 431 | 0.440 |
Why?
|
| Ki-1 Antigen | 4 | 2020 | 30 | 0.440 |
Why?
|
| Organic Chemicals | 6 | 2015 | 58 | 0.410 |
Why?
|
| Interleukin-4 | 9 | 2018 | 144 | 0.410 |
Why?
|
| Recombinant Proteins | 19 | 2015 | 1295 | 0.410 |
Why?
|
| Sialoglycoproteins | 4 | 2007 | 42 | 0.410 |
Why?
|
| Cell Differentiation | 13 | 2015 | 1871 | 0.400 |
Why?
|
| Leukemia, B-Cell | 4 | 2010 | 23 | 0.400 |
Why?
|
| Bone Marrow Purging | 11 | 2007 | 34 | 0.390 |
Why?
|
| Salvage Therapy | 4 | 2021 | 173 | 0.390 |
Why?
|
| Clinical Trials as Topic | 16 | 2016 | 1110 | 0.390 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 198 | 0.390 |
Why?
|
| Herpesviridae Infections | 11 | 2013 | 139 | 0.390 |
Why?
|
| Cytomegalovirus Infections | 8 | 2013 | 219 | 0.390 |
Why?
|
| Journal Impact Factor | 1 | 2012 | 24 | 0.380 |
Why?
|
| Growth Substances | 6 | 1996 | 106 | 0.380 |
Why?
|
| Young Adult | 20 | 2024 | 9705 | 0.370 |
Why?
|
| Stem Cells | 10 | 2014 | 682 | 0.370 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2011 | 70 | 0.370 |
Why?
|
| Graft Rejection | 10 | 2020 | 559 | 0.360 |
Why?
|
| Antigen Presentation | 10 | 2010 | 116 | 0.360 |
Why?
|
| Antigens, Viral | 15 | 2013 | 392 | 0.360 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2003 | 101 | 0.360 |
Why?
|
| Antigen-Presenting Cells | 7 | 2007 | 133 | 0.360 |
Why?
|
| Stem Cell Research | 1 | 2011 | 5 | 0.360 |
Why?
|
| Bone Marrow | 12 | 2020 | 308 | 0.360 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 4445 | 0.360 |
Why?
|
| B7-H1 Antigen | 4 | 2021 | 125 | 0.350 |
Why?
|
| Vidarabine | 7 | 2024 | 85 | 0.350 |
Why?
|
| CD3 Complex | 10 | 2015 | 91 | 0.350 |
Why?
|
| Chemokines, C | 3 | 2002 | 10 | 0.340 |
Why?
|
| Glioblastoma | 4 | 2017 | 335 | 0.340 |
Why?
|
| Bibliometrics | 1 | 2011 | 39 | 0.340 |
Why?
|
| Immunosuppressive Agents | 10 | 2015 | 654 | 0.340 |
Why?
|
| Epitopes, T-Lymphocyte | 7 | 2014 | 131 | 0.340 |
Why?
|
| Epitopes | 7 | 2020 | 420 | 0.340 |
Why?
|
| Cell Transplantation | 6 | 2016 | 35 | 0.340 |
Why?
|
| Biomedical Research | 2 | 2014 | 534 | 0.340 |
Why?
|
| Biological Therapy | 1 | 2010 | 25 | 0.330 |
Why?
|
| Histocompatibility | 6 | 2006 | 42 | 0.330 |
Why?
|
| Glial Fibrillary Acidic Protein | 8 | 2001 | 101 | 0.320 |
Why?
|
| Aged | 30 | 2026 | 20519 | 0.320 |
Why?
|
| Drug Resistance | 11 | 2009 | 246 | 0.320 |
Why?
|
| T-Cell Antigen Receptor Specificity | 6 | 2021 | 55 | 0.320 |
Why?
|
| Interleukin-7 | 4 | 2017 | 45 | 0.320 |
Why?
|
| Lentivirus | 6 | 2017 | 79 | 0.320 |
Why?
|
| Thrombocytopenia | 4 | 2024 | 222 | 0.320 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2010 | 34 | 0.310 |
Why?
|
| Immunization | 7 | 2010 | 304 | 0.310 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 2314 | 0.310 |
Why?
|
| Receptors, Antigen | 1 | 2009 | 33 | 0.310 |
Why?
|
| Immunity | 5 | 2009 | 175 | 0.310 |
Why?
|
| Simplexvirus | 6 | 2003 | 100 | 0.310 |
Why?
|
| Remission Induction | 15 | 2020 | 299 | 0.300 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2893 | 0.300 |
Why?
|
| Cell Separation | 14 | 2018 | 220 | 0.300 |
Why?
|
| Myeloid Cells | 4 | 2018 | 106 | 0.300 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.300 |
Why?
|
| Alemtuzumab | 8 | 2018 | 87 | 0.290 |
Why?
|
| Immunotoxins | 4 | 2015 | 21 | 0.290 |
Why?
|
| Killer Cells, Lymphokine-Activated | 4 | 1993 | 8 | 0.290 |
Why?
|
| Precision Medicine | 1 | 2012 | 347 | 0.290 |
Why?
|
| Lymphocyte Count | 5 | 2018 | 117 | 0.280 |
Why?
|
| Infant | 37 | 2024 | 12810 | 0.280 |
Why?
|
| Adenoviridae Infections | 5 | 2013 | 70 | 0.280 |
Why?
|
| Nasopharyngeal Neoplasms | 5 | 2024 | 61 | 0.280 |
Why?
|
| Phenotype | 15 | 2018 | 4309 | 0.270 |
Why?
|
| Sarcoma | 2 | 2024 | 206 | 0.270 |
Why?
|
| Osteogenesis Imperfecta | 2 | 2001 | 167 | 0.270 |
Why?
|
| Virus Integration | 4 | 2015 | 37 | 0.270 |
Why?
|
| Neoplasm Proteins | 6 | 2018 | 656 | 0.270 |
Why?
|
| Cyclophosphamide | 8 | 2024 | 425 | 0.270 |
Why?
|
| Polymerase Chain Reaction | 15 | 2008 | 1485 | 0.270 |
Why?
|
| Liposomes | 4 | 2004 | 196 | 0.270 |
Why?
|
| Haplotypes | 4 | 2015 | 525 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 13 | 2023 | 342 | 0.260 |
Why?
|
| Cell Division | 15 | 2006 | 719 | 0.260 |
Why?
|
| Mice, Inbred NOD | 9 | 2021 | 290 | 0.260 |
Why?
|
| Brain Neoplasms | 5 | 2021 | 1235 | 0.260 |
Why?
|
| Herpesvirus 6, Human | 4 | 2017 | 54 | 0.250 |
Why?
|
| Immunization, Passive | 9 | 2001 | 120 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1310 | 0.250 |
Why?
|
| Glycoproteins | 3 | 2022 | 338 | 0.250 |
Why?
|
| Models, Immunological | 4 | 2010 | 37 | 0.250 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 4 | 2014 | 58 | 0.250 |
Why?
|
| Astrocytes | 8 | 2001 | 262 | 0.250 |
Why?
|
| Membrane Proteins | 3 | 2003 | 1569 | 0.250 |
Why?
|
| Recovery of Function | 2 | 2005 | 440 | 0.240 |
Why?
|
| HLA Antigens | 6 | 2010 | 217 | 0.240 |
Why?
|
| Hematopoiesis | 7 | 2011 | 205 | 0.240 |
Why?
|
| Receptors, Cell Surface | 4 | 2004 | 422 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 1601 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2016 | 787 | 0.230 |
Why?
|
| DNA Viruses | 2 | 2017 | 30 | 0.230 |
Why?
|
| Glioma | 6 | 2024 | 480 | 0.230 |
Why?
|
| CD8 Antigens | 4 | 2020 | 40 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2010 | 776 | 0.230 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2011 | 34 | 0.230 |
Why?
|
| Roseolovirus Infections | 3 | 2012 | 30 | 0.230 |
Why?
|
| Tumor Necrosis Factors | 1 | 2004 | 11 | 0.220 |
Why?
|
| ATP-Binding Cassette Transporters | 4 | 2010 | 189 | 0.220 |
Why?
|
| Carboplatin | 2 | 2024 | 77 | 0.220 |
Why?
|
| Peritoneal Neoplasms | 1 | 2025 | 53 | 0.220 |
Why?
|
| Granulomatous Disease, Chronic | 2 | 2018 | 70 | 0.220 |
Why?
|
| Enzyme Activation | 4 | 2015 | 578 | 0.220 |
Why?
|
| Receptors, Interleukin-7 | 4 | 2014 | 25 | 0.220 |
Why?
|
| Mutant Chimeric Proteins | 3 | 2017 | 14 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 40 | 0.220 |
Why?
|
| Autoantigens | 2 | 2004 | 104 | 0.220 |
Why?
|
| Transplantation Chimera | 5 | 2015 | 45 | 0.220 |
Why?
|
| Tumor Virus Infections | 9 | 1998 | 131 | 0.210 |
Why?
|
| Cellular Senescence | 3 | 2024 | 199 | 0.210 |
Why?
|
| Time Factors | 20 | 2018 | 6171 | 0.210 |
Why?
|
| Deoxycytidine | 1 | 2024 | 82 | 0.210 |
Why?
|
| Immunologic Memory | 8 | 2011 | 194 | 0.210 |
Why?
|
| Prodrugs | 4 | 2016 | 53 | 0.210 |
Why?
|
| Clinical Protocols | 10 | 2000 | 228 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2016 | 542 | 0.210 |
Why?
|
| DNA Virus Infections | 2 | 2017 | 22 | 0.210 |
Why?
|
| A549 Cells | 2 | 2021 | 49 | 0.200 |
Why?
|
| Immunocompromised Host | 7 | 2014 | 303 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2021 | 124 | 0.200 |
Why?
|
| Fibroblasts | 8 | 2004 | 820 | 0.200 |
Why?
|
| Antigens, CD34 | 9 | 2001 | 99 | 0.200 |
Why?
|
| Plasmids | 7 | 2011 | 445 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2024 | 192 | 0.200 |
Why?
|
| Neoplasm Transplantation | 8 | 2023 | 361 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 1997 | 69 | 0.200 |
Why?
|
| Complement Activation | 1 | 2003 | 49 | 0.200 |
Why?
|
| Lectins | 1 | 2023 | 49 | 0.200 |
Why?
|
| Acute Disease | 11 | 2011 | 1142 | 0.190 |
Why?
|
| Tacrolimus Binding Protein 1A | 2 | 2015 | 21 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 53 | 0.190 |
Why?
|
| Plasmacytoma | 1 | 2002 | 10 | 0.190 |
Why?
|
| Blood Component Removal | 1 | 2002 | 35 | 0.190 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 2010 | 56 | 0.190 |
Why?
|
| Mesoderm | 2 | 2001 | 104 | 0.190 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2016 | 29 | 0.190 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 5160 | 0.190 |
Why?
|
| Osteoblasts | 2 | 2003 | 160 | 0.190 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2017 | 32 | 0.180 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2004 | 50 | 0.180 |
Why?
|
| Prostatic Neoplasms | 4 | 2013 | 1395 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 7 | 2010 | 1000 | 0.180 |
Why?
|
| Blood Platelets | 2 | 2024 | 312 | 0.180 |
Why?
|
| Antigens, CD7 | 3 | 2018 | 11 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2017 | 48 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 6 | 2018 | 447 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2002 | 116 | 0.170 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 28 | 0.170 |
Why?
|
| Antigens | 5 | 2014 | 146 | 0.170 |
Why?
|
| Busulfan | 3 | 2023 | 46 | 0.170 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2008 | 105 | 0.170 |
Why?
|
| Virus Activation | 6 | 2012 | 84 | 0.170 |
Why?
|
| Peptides | 5 | 2016 | 830 | 0.170 |
Why?
|
| Leukemia, Experimental | 2 | 1997 | 16 | 0.170 |
Why?
|
| K562 Cells | 5 | 2011 | 95 | 0.170 |
Why?
|
| Immunoglobulin G | 17 | 2014 | 793 | 0.170 |
Why?
|
| Neomycin | 7 | 2000 | 36 | 0.170 |
Why?
|
| Adenoviruses, Human | 6 | 2017 | 93 | 0.170 |
Why?
|
| Viral Tropism | 1 | 2021 | 41 | 0.170 |
Why?
|
| RNA, Messenger | 13 | 2009 | 2542 | 0.170 |
Why?
|
| DNA, Viral | 10 | 2009 | 448 | 0.170 |
Why?
|
| Survival Analysis | 8 | 2018 | 1501 | 0.170 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 900 | 0.170 |
Why?
|
| Signal Transduction | 8 | 2018 | 4489 | 0.160 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 22 | 0.160 |
Why?
|
| Fetal Blood | 4 | 2010 | 174 | 0.160 |
Why?
|
| Anemia | 2 | 2024 | 341 | 0.160 |
Why?
|
| Central Nervous System Diseases | 1 | 2001 | 94 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 130 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 1994 | 77 | 0.160 |
Why?
|
| Receptors, Interleukin-2 | 6 | 2005 | 40 | 0.150 |
Why?
|
| Leukemia, Lymphoid | 8 | 1999 | 99 | 0.150 |
Why?
|
| Histocompatibility Testing | 7 | 2009 | 105 | 0.150 |
Why?
|
| Transplantation Immunology | 4 | 2006 | 41 | 0.150 |
Why?
|
| Unrelated Donors | 3 | 2018 | 72 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 7 | 2014 | 377 | 0.150 |
Why?
|
| Growth Inhibitors | 4 | 1998 | 37 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 60 | 0.150 |
Why?
|
| Protein Multimerization | 2 | 2016 | 138 | 0.150 |
Why?
|
| Feasibility Studies | 6 | 2022 | 799 | 0.150 |
Why?
|
| Immune Tolerance | 5 | 2004 | 154 | 0.150 |
Why?
|
| Graft Survival | 6 | 2008 | 455 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 6 | 2020 | 62 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 631 | 0.150 |
Why?
|
| Cell Line, Transformed | 9 | 2010 | 156 | 0.140 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 3588 | 0.140 |
Why?
|
| Hematologic Diseases | 4 | 1995 | 75 | 0.140 |
Why?
|
| Societies, Scientific | 2 | 2011 | 24 | 0.140 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2017 | 8 | 0.140 |
Why?
|
| 4-1BB Ligand | 1 | 2017 | 11 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Proteins | 1 | 2003 | 1019 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2010 | 57 | 0.140 |
Why?
|
| Interferon Type I | 4 | 2017 | 108 | 0.140 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2017 | 31 | 0.140 |
Why?
|
| Antigens, CD1 | 1 | 1997 | 23 | 0.130 |
Why?
|
| Immune System | 2 | 2010 | 93 | 0.130 |
Why?
|
| Immunological Synapses | 1 | 2017 | 32 | 0.130 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 210 | 0.130 |
Why?
|
| Peptide Fragments | 7 | 2011 | 762 | 0.130 |
Why?
|
| Safety | 5 | 2007 | 211 | 0.130 |
Why?
|
| Carcinoma | 2 | 2010 | 279 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2018 | 264 | 0.130 |
Why?
|
| Whole-Body Irradiation | 5 | 2006 | 59 | 0.130 |
Why?
|
| History, 20th Century | 2 | 2014 | 370 | 0.130 |
Why?
|
| Tetanus Toxoid | 5 | 1988 | 48 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 92 | 0.130 |
Why?
|
| Immunoglobulins | 3 | 1992 | 156 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 972 | 0.130 |
Why?
|
| Mucin-1 | 2 | 2013 | 34 | 0.130 |
Why?
|
| Lymphocyte Cooperation | 6 | 1990 | 11 | 0.130 |
Why?
|
| Ricin | 2 | 1994 | 9 | 0.130 |
Why?
|
| Platelet Function Tests | 1 | 2016 | 39 | 0.130 |
Why?
|
| Hemorrhagic Disorders | 1 | 2016 | 22 | 0.120 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2016 | 20 | 0.120 |
Why?
|
| Base Sequence | 11 | 2001 | 2760 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 606 | 0.120 |
Why?
|
| Injections, Intralesional | 2 | 2015 | 43 | 0.120 |
Why?
|
| Hematocrit | 1 | 2016 | 110 | 0.120 |
Why?
|
| Platelet Count | 1 | 2016 | 132 | 0.120 |
Why?
|
| Methylprednisolone | 2 | 1995 | 93 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 524 | 0.120 |
Why?
|
| Melanoma | 2 | 2016 | 898 | 0.120 |
Why?
|
| Somatostatin | 1 | 1996 | 60 | 0.120 |
Why?
|
| Single-Chain Antibodies | 2 | 2021 | 36 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 1932 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 223 | 0.120 |
Why?
|
| Transcription Factors | 3 | 2002 | 2345 | 0.120 |
Why?
|
| Gentamicins | 3 | 1992 | 85 | 0.120 |
Why?
|
| Receptors, Virus | 2 | 2010 | 89 | 0.120 |
Why?
|
| Fibronectins | 2 | 2015 | 99 | 0.120 |
Why?
|
| Living Donors | 3 | 2008 | 115 | 0.120 |
Why?
|
| Hyaluronan Receptors | 2 | 2020 | 64 | 0.120 |
Why?
|
| Fibrin | 1 | 2016 | 64 | 0.120 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 689 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 1998 | 222 | 0.120 |
Why?
|
| Capsid Proteins | 2 | 2007 | 143 | 0.120 |
Why?
|
| Immunity, Cellular | 5 | 2018 | 196 | 0.120 |
Why?
|
| Clone Cells | 5 | 2008 | 163 | 0.120 |
Why?
|
| Protein Conformation | 1 | 1997 | 802 | 0.120 |
Why?
|
| B7-2 Antigen | 2 | 2005 | 16 | 0.120 |
Why?
|
| Gene Order | 1 | 2015 | 78 | 0.110 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 22 | 0.110 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 24 | 0.110 |
Why?
|
| Muromonab-CD3 | 1 | 2015 | 7 | 0.110 |
Why?
|
| Mesna | 2 | 1994 | 7 | 0.110 |
Why?
|
| Cell Culture Techniques | 5 | 2010 | 271 | 0.110 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2006 | 105 | 0.110 |
Why?
|
| Granulocytes | 3 | 1991 | 68 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 735 | 0.110 |
Why?
|
| Kinetics | 5 | 2011 | 1092 | 0.110 |
Why?
|
| Rats | 9 | 2009 | 3397 | 0.110 |
Why?
|
| Phosphoproteins | 3 | 2008 | 420 | 0.110 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1991 | 9 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2014 | 47 | 0.110 |
Why?
|
| Siblings | 3 | 2015 | 202 | 0.110 |
Why?
|
| Postoperative Complications | 8 | 2010 | 3076 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 240 | 0.110 |
Why?
|
| Antigens, CD20 | 4 | 2006 | 40 | 0.110 |
Why?
|
| Immunoglobulin M | 9 | 1995 | 211 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 6718 | 0.110 |
Why?
|
| Antiviral Agents | 3 | 2014 | 776 | 0.110 |
Why?
|
| Luminescent Proteins | 4 | 2003 | 155 | 0.110 |
Why?
|
| Models, Biological | 3 | 2016 | 1374 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 13 | 0.110 |
Why?
|
| Pyrazines | 1 | 2014 | 77 | 0.110 |
Why?
|
| Skin Ulcer | 1 | 2014 | 31 | 0.110 |
Why?
|
| Antibodies, Viral | 7 | 2007 | 1133 | 0.110 |
Why?
|
| Teratoma | 1 | 2015 | 120 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.110 |
Why?
|
| Speech Acoustics | 1 | 1994 | 9 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2009 | 209 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2012 | 299 | 0.100 |
Why?
|
| Amino Acid Sequence | 9 | 2013 | 2543 | 0.100 |
Why?
|
| Leukocytes | 2 | 2015 | 204 | 0.100 |
Why?
|
| Antigens, Surface | 5 | 2004 | 114 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 1996 | 275 | 0.100 |
Why?
|
| Aphthovirus | 1 | 2013 | 3 | 0.100 |
Why?
|
| RNA Viruses | 1 | 2013 | 32 | 0.100 |
Why?
|
| Risk Factors | 11 | 2017 | 10636 | 0.100 |
Why?
|
| Tacrolimus | 3 | 2009 | 100 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2024 | 4988 | 0.100 |
Why?
|
| Kanamycin Kinase | 6 | 1998 | 15 | 0.100 |
Why?
|
| Immunologic Factors | 3 | 2009 | 182 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 203 | 0.100 |
Why?
|
| Stromal Cells | 2 | 2016 | 307 | 0.100 |
Why?
|
| DNA | 7 | 2008 | 1422 | 0.100 |
Why?
|
| Flutamide | 1 | 2013 | 27 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Antibodies, Bacterial | 3 | 1990 | 421 | 0.100 |
Why?
|
| Burkitt Lymphoma | 3 | 2006 | 132 | 0.100 |
Why?
|
| Integrins | 3 | 2004 | 88 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 669 | 0.100 |
Why?
|
| Biomarkers | 5 | 2010 | 3253 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1993 | 37 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 8 | 2010 | 4513 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 5 | 1997 | 33 | 0.100 |
Why?
|
| Tumor Burden | 3 | 2021 | 231 | 0.100 |
Why?
|
| Oligopeptides | 3 | 2004 | 115 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 373 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 60 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 1994 | 174 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 131 | 0.100 |
Why?
|
| Infusions, Intravenous | 7 | 2010 | 537 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 200 | 0.100 |
Why?
|
| Cerebellum | 1 | 1996 | 414 | 0.090 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1992 | 26 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 95 | 0.090 |
Why?
|
| Leukocyte Count | 5 | 2002 | 247 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2022 | 17081 | 0.090 |
Why?
|
| Placenta | 1 | 1996 | 518 | 0.090 |
Why?
|
| Viral Proteins | 3 | 2004 | 336 | 0.090 |
Why?
|
| Nanotechnology | 1 | 2012 | 48 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 591 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 261 | 0.090 |
Why?
|
| CD27 Ligand | 1 | 2011 | 5 | 0.090 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 12 | 0.090 |
Why?
|
| Antilymphocyte Serum | 3 | 2006 | 43 | 0.090 |
Why?
|
| Ganciclovir | 4 | 2001 | 101 | 0.090 |
Why?
|
| Gold | 1 | 2012 | 52 | 0.090 |
Why?
|
| Graft vs Host Reaction | 1 | 1991 | 10 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 7 | 2015 | 1206 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 743 | 0.090 |
Why?
|
| fas Receptor | 2 | 2017 | 43 | 0.090 |
Why?
|
| Standard of Care | 1 | 2012 | 133 | 0.090 |
Why?
|
| Cell Movement | 3 | 2010 | 852 | 0.090 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 23 | 0.090 |
Why?
|
| Metal Nanoparticles | 1 | 2012 | 54 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 258 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2011 | 720 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2024 | 1199 | 0.090 |
Why?
|
| Interleukin-6 | 3 | 2024 | 406 | 0.090 |
Why?
|
| Multiple Sclerosis | 3 | 2004 | 373 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2005 | 74 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 253 | 0.090 |
Why?
|
| Peptide Library | 3 | 2011 | 57 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.080 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2011 | 68 | 0.080 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 71 | 0.080 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 21 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2010 | 2311 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2024 | 6250 | 0.080 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 23 | 0.080 |
Why?
|
| Bone Transplantation | 1 | 1991 | 50 | 0.080 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 14 | 0.080 |
Why?
|
| Cell Transformation, Viral | 5 | 2003 | 95 | 0.080 |
Why?
|
| Enzyme Induction | 2 | 2014 | 97 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 25 | 0.080 |
Why?
|
| Osteogenesis | 2 | 2003 | 162 | 0.080 |
Why?
|
| HIV-1 | 3 | 2000 | 469 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2012 | 450 | 0.080 |
Why?
|
| Prognosis | 7 | 2021 | 4804 | 0.080 |
Why?
|
| NF-kappa B | 2 | 2017 | 438 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 161 | 0.080 |
Why?
|
| Blotting, Western | 5 | 2015 | 1016 | 0.080 |
Why?
|
| Colony-Stimulating Factors | 1 | 1989 | 3 | 0.080 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 53 | 0.080 |
Why?
|
| In Vitro Techniques | 8 | 2016 | 826 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2004 | 109 | 0.080 |
Why?
|
| Heterografts | 2 | 2023 | 190 | 0.080 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1989 | 17 | 0.080 |
Why?
|
| Genes, Viral | 3 | 2001 | 156 | 0.080 |
Why?
|
| Homeostasis | 2 | 1991 | 692 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 662 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 1990 | 114 | 0.080 |
Why?
|
| Receptors, Immunologic | 3 | 2004 | 118 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Genetic Techniques | 1 | 2010 | 99 | 0.080 |
Why?
|
| Adenovirus Infections, Human | 1 | 2009 | 52 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1990 | 172 | 0.080 |
Why?
|
| Genes, Synthetic | 1 | 2009 | 13 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 153 | 0.070 |
Why?
|
| Survival Rate | 5 | 2017 | 2111 | 0.070 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1999 | 47 | 0.070 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 5 | 1993 | 15 | 0.070 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1999 | 19 | 0.070 |
Why?
|
| Aging | 1 | 1996 | 1207 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 1055 | 0.070 |
Why?
|
| Allografts | 2 | 2021 | 189 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 1994 | 553 | 0.070 |
Why?
|
| Fever | 2 | 2010 | 309 | 0.070 |
Why?
|
| Thalassemia | 2 | 1987 | 9 | 0.070 |
Why?
|
| Biological Factors | 1 | 1988 | 26 | 0.070 |
Why?
|
| Blood Cells | 3 | 2010 | 55 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2009 | 154 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 764 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2009 | 363 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 149 | 0.070 |
Why?
|
| Anemia, Aplastic | 3 | 2006 | 58 | 0.070 |
Why?
|
| Donor Selection | 1 | 2008 | 58 | 0.070 |
Why?
|
| Mutation | 2 | 2002 | 5949 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 364 | 0.070 |
Why?
|
| DNA, Cruciform | 1 | 2008 | 18 | 0.070 |
Why?
|
| Antigens, Fungal | 1 | 2007 | 34 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 1206 | 0.070 |
Why?
|
| Chimera | 2 | 2003 | 80 | 0.070 |
Why?
|
| Cell Death | 3 | 2017 | 237 | 0.070 |
Why?
|
| Bone Density | 2 | 2001 | 354 | 0.070 |
Why?
|
| Caspases | 2 | 2005 | 156 | 0.070 |
Why?
|
| Mitoxantrone | 2 | 2004 | 27 | 0.070 |
Why?
|
| Immunodominant Epitopes | 2 | 2012 | 53 | 0.070 |
Why?
|
| Organ Specificity | 3 | 2018 | 395 | 0.070 |
Why?
|
| Thymidine Kinase | 2 | 1998 | 88 | 0.070 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2007 | 9 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 21 | 0.070 |
Why?
|
| Injections, Subcutaneous | 3 | 2008 | 129 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 128 | 0.060 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 28 | 0.060 |
Why?
|
| Chondrogenesis | 1 | 2007 | 27 | 0.060 |
Why?
|
| Pneumonia | 2 | 1987 | 336 | 0.060 |
Why?
|
| Cross Reactions | 2 | 2004 | 181 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2014 | 770 | 0.060 |
Why?
|
| Drug Design | 1 | 2008 | 153 | 0.060 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 37 | 0.060 |
Why?
|
| Serrate-Jagged Proteins | 2 | 2003 | 36 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2007 | 47 | 0.060 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2008 | 104 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 4 | 1998 | 195 | 0.060 |
Why?
|
| Glycolipids | 2 | 1997 | 33 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 173 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2001 | 22 | 0.060 |
Why?
|
| Jagged-1 Protein | 2 | 2003 | 51 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2080 | 0.060 |
Why?
|
| Isoantigens | 2 | 2003 | 23 | 0.060 |
Why?
|
| Benzimidazoles | 2 | 2004 | 151 | 0.060 |
Why?
|
| Antibody Specificity | 3 | 2001 | 199 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2006 | 51 | 0.060 |
Why?
|
| Regeneration | 1 | 1988 | 206 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 318 | 0.060 |
Why?
|
| HLA-A Antigens | 4 | 2011 | 31 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2008 | 251 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2587 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 1991 | 376 | 0.060 |
Why?
|
| CD52 Antigen | 1 | 2005 | 6 | 0.060 |
Why?
|
| Monocytes | 3 | 2012 | 330 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2014 | 73 | 0.060 |
Why?
|
| Microscopy, Electron | 3 | 2002 | 309 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 291 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 2 | 2003 | 327 | 0.060 |
Why?
|
| Virus Latency | 2 | 2006 | 61 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2018 | 8371 | 0.060 |
Why?
|
| B7-1 Antigen | 1 | 2004 | 11 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 289 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 303 | 0.060 |
Why?
|
| OX40 Ligand | 1 | 2004 | 9 | 0.060 |
Why?
|
| Granzymes | 1 | 2004 | 46 | 0.060 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cell-Free System | 4 | 1992 | 62 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 158 | 0.060 |
Why?
|
| Receptors, Notch | 2 | 2003 | 195 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2004 | 827 | 0.060 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 63 | 0.050 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 6 | 1990 | 59 | 0.050 |
Why?
|
| Cell Fusion | 1 | 2004 | 33 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2007 | 1232 | 0.050 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2004 | 7 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Neurons | 3 | 2001 | 1922 | 0.050 |
Why?
|
| Age Distribution | 1 | 2005 | 423 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 89 | 0.050 |
Why?
|
| CD4 Antigens | 2 | 2002 | 50 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 191 | 0.050 |
Why?
|
| Ethics Committees, Clinical | 1 | 2003 | 18 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 129 | 0.050 |
Why?
|
| Nuclear Family | 2 | 2001 | 49 | 0.050 |
Why?
|
| Histocompatibility Antigens | 2 | 2007 | 15 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 3 | 1998 | 60 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2003 | 5 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2004 | 769 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 248 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2003 | 65 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2003 | 38 | 0.050 |
Why?
|
| HLA-DP Antigens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Calcimycin | 5 | 1989 | 19 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2017 | 708 | 0.050 |
Why?
|
| Thymus Gland | 2 | 2004 | 100 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 332 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 288 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2008 | 1601 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 45 | 0.050 |
Why?
|
| Dasatinib | 1 | 2022 | 48 | 0.050 |
Why?
|
| Spleen | 3 | 2006 | 254 | 0.050 |
Why?
|
| Oxidopamine | 2 | 1999 | 13 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1994 | 241 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2021 | 10 | 0.050 |
Why?
|
| Genes, myc | 1 | 2002 | 95 | 0.050 |
Why?
|
| Macrophages | 2 | 2000 | 643 | 0.050 |
Why?
|
| Blast Crisis | 2 | 1992 | 16 | 0.040 |
Why?
|
| Neutrophils | 2 | 2002 | 355 | 0.040 |
Why?
|
| Polynucleotides | 1 | 2001 | 7 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2008 | 1406 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2002 | 19 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2001 | 13 | 0.040 |
Why?
|
| Phosphotransferases | 2 | 1992 | 33 | 0.040 |
Why?
|
| Prednisone | 2 | 2014 | 241 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2001 | 23 | 0.040 |
Why?
|
| United States | 6 | 2011 | 11428 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2022 | 140 | 0.040 |
Why?
|
| Hemocyanins | 2 | 1992 | 24 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 289 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 2048 | 0.040 |
Why?
|
| Fractures, Spontaneous | 1 | 2001 | 18 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 2001 | 73 | 0.040 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 39 | 0.040 |
Why?
|
| Leukopoiesis | 1 | 2000 | 2 | 0.040 |
Why?
|
| Neutropenia | 3 | 1992 | 198 | 0.040 |
Why?
|
| Psychomotor Disorders | 1 | 2001 | 29 | 0.040 |
Why?
|
| Interferon-alpha | 2 | 1993 | 237 | 0.040 |
Why?
|
| Disease Progression | 3 | 2017 | 2125 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 973 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 16 | 0.040 |
Why?
|
| HIV Infections | 2 | 2007 | 1954 | 0.040 |
Why?
|
| Dimerization | 2 | 2014 | 135 | 0.040 |
Why?
|
| Integrases | 1 | 2001 | 153 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 565 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2000 | 75 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 3 | 2006 | 54 | 0.040 |
Why?
|
| Pancytopenia | 2 | 2018 | 40 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 1998 | 1438 | 0.040 |
Why?
|
| Antigens, Differentiation | 3 | 1995 | 63 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 174 | 0.040 |
Why?
|
| Body Height | 1 | 2001 | 192 | 0.040 |
Why?
|
| Europe | 1 | 2001 | 363 | 0.040 |
Why?
|
| Utah | 1 | 1999 | 82 | 0.040 |
Why?
|
| Neuroglia | 1 | 2001 | 208 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 40 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 48 | 0.040 |
Why?
|
| Quality of Life | 2 | 2024 | 2032 | 0.040 |
Why?
|
| Mifepristone | 1 | 1999 | 87 | 0.040 |
Why?
|
| Postoperative Period | 4 | 1988 | 325 | 0.040 |
Why?
|
| CD40 Antigens | 1 | 1999 | 24 | 0.040 |
Why?
|
| Tetracycline | 1 | 1999 | 80 | 0.040 |
Why?
|
| Drug Therapy | 1 | 1999 | 83 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2002 | 435 | 0.040 |
Why?
|
| Age of Onset | 1 | 2001 | 611 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2001 | 174 | 0.040 |
Why?
|
| Norway | 1 | 1999 | 29 | 0.040 |
Why?
|
| Vaccines, Synthetic | 2 | 2004 | 316 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2015 | 649 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 784 | 0.040 |
Why?
|
| Biopsy | 2 | 2020 | 1237 | 0.040 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2018 | 5 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1999 | 80 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2001 | 414 | 0.040 |
Why?
|
| Retinal Neoplasms | 1 | 1999 | 69 | 0.040 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1998 | 16 | 0.040 |
Why?
|
| Treatment Failure | 1 | 1999 | 339 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 220 | 0.040 |
Why?
|
| Viral Load | 3 | 2004 | 398 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 1998 | 38 | 0.040 |
Why?
|
| Gene Amplification | 2 | 2002 | 228 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| RNA, Catalytic | 1 | 1998 | 14 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 75 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 30 | 0.030 |
Why?
|
| Graft vs Tumor Effect | 1 | 1998 | 8 | 0.030 |
Why?
|
| Forecasting | 2 | 1996 | 361 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 1997 | 12 | 0.030 |
Why?
|
| Chromatin | 2 | 2015 | 472 | 0.030 |
Why?
|
| Gammaretrovirus | 1 | 2017 | 6 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 104 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 677 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1997 | 85 | 0.030 |
Why?
|
| beta-Galactosidase | 3 | 2004 | 135 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 237 | 0.030 |
Why?
|
| X Chromosome | 1 | 1998 | 329 | 0.030 |
Why?
|
| Sirolimus | 1 | 1999 | 223 | 0.030 |
Why?
|
| HLA-A2 Antigen | 2 | 2011 | 26 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 65 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 1997 | 83 | 0.030 |
Why?
|
| Cell Hypoxia | 2 | 2008 | 85 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1998 | 138 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2014 | 292 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2002 | 1892 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 49 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 58 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2001 | 979 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 90 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 3 | 1998 | 2519 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 1996 | 29 | 0.030 |
Why?
|
| Centrifugation | 1 | 2016 | 23 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 253 | 0.030 |
Why?
|
| Receptors, Dopamine | 2 | 1987 | 30 | 0.030 |
Why?
|
| Interleukin-3 | 2 | 1999 | 17 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2008 | 241 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 52 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 224 | 0.030 |
Why?
|
| Benzazepines | 2 | 1987 | 43 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2016 | 61 | 0.030 |
Why?
|
| P-Selectin | 1 | 2016 | 68 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2016 | 66 | 0.030 |
Why?
|
| HLA-DR Antigens | 3 | 1996 | 69 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2016 | 94 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 24 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 31 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2014 | 784 | 0.030 |
Why?
|
| Vaccination | 2 | 2007 | 1004 | 0.030 |
Why?
|
| Seizures | 1 | 2001 | 847 | 0.030 |
Why?
|
| Membrane Lipids | 1 | 1995 | 31 | 0.030 |
Why?
|
| Liver | 2 | 2003 | 1765 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 95 | 0.030 |
Why?
|
| Conserved Sequence | 2 | 2007 | 279 | 0.030 |
Why?
|
| Th2 Cells | 2 | 2009 | 186 | 0.030 |
Why?
|
| Interleukins | 2 | 1994 | 119 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Mitosis | 1 | 1996 | 190 | 0.030 |
Why?
|
| Supratentorial Neoplasms | 1 | 1995 | 36 | 0.030 |
Why?
|
| Globins | 1 | 1995 | 24 | 0.030 |
Why?
|
| Luciferases, Firefly | 1 | 2014 | 10 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 11 | 0.030 |
Why?
|
| Jurkat Cells | 2 | 2005 | 84 | 0.030 |
Why?
|
| Incidence | 3 | 2018 | 3264 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1998 | 225 | 0.030 |
Why?
|
| RNA | 1 | 1998 | 518 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 70 | 0.030 |
Why?
|
| Informed Consent | 2 | 1994 | 338 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1997 | 355 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 333 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 43 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 44 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1996 | 314 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 1999 | 3720 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 46 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 111 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 637 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1996 | 447 | 0.030 |
Why?
|
| Cyclosporine | 2 | 2006 | 127 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 496 | 0.030 |
Why?
|
| Lipids | 1 | 1997 | 551 | 0.030 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1994 | 44 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1990 | 173 | 0.030 |
Why?
|
| Transcobalamins | 1 | 1993 | 4 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1999 | 662 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1990 | 102 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1069 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 60 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 516 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 372 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2013 | 31 | 0.030 |
Why?
|
| Respirovirus Infections | 1 | 1993 | 20 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1996 | 399 | 0.030 |
Why?
|
| Cell Count | 2 | 1996 | 218 | 0.020 |
Why?
|
| Blood Donors | 2 | 2011 | 55 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 1993 | 57 | 0.020 |
Why?
|
| Organoids | 1 | 2016 | 283 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 735 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1993 | 150 | 0.020 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 149 | 0.020 |
Why?
|
| Research | 1 | 1994 | 257 | 0.020 |
Why?
|
| Immunoradiometric Assay | 1 | 1992 | 2 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1993 | 190 | 0.020 |
Why?
|
| CD11 Antigens | 1 | 1992 | 10 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 144 | 0.020 |
Why?
|
| Suspensions | 1 | 2012 | 8 | 0.020 |
Why?
|
| Reference Values | 1 | 1994 | 687 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 108 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 11 | 0.020 |
Why?
|
| Mollusca | 1 | 1992 | 10 | 0.020 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 1993 | 149 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2012 | 82 | 0.020 |
Why?
|
| Sex Factors | 1 | 1996 | 1315 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 217 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 261 | 0.020 |
Why?
|
| Injections | 1 | 2012 | 114 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 12 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1994 | 174 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1991 | 17 | 0.020 |
Why?
|
| Probability | 1 | 1992 | 308 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 296 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1011 | 0.020 |
Why?
|
| TATA Box | 1 | 1990 | 15 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 1991 | 66 | 0.020 |
Why?
|
| Hippocampus | 1 | 1996 | 780 | 0.020 |
Why?
|
| Bacterial Infections | 2 | 1996 | 322 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1991 | 42 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 573 | 0.020 |
Why?
|
| Immune Evasion | 1 | 2011 | 38 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 276 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1990 | 131 | 0.020 |
Why?
|
| Vimentin | 1 | 1990 | 63 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 175 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 11 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 111 | 0.020 |
Why?
|
| Blotting, Northern | 3 | 2001 | 235 | 0.020 |
Why?
|
| Plasma Cells | 1 | 1990 | 54 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1990 | 149 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2008 | 684 | 0.020 |
Why?
|
| Vaccines | 1 | 1995 | 381 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1989 | 34 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 151 | 0.020 |
Why?
|
| Research Design | 1 | 1994 | 694 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 48 | 0.020 |
Why?
|
| Telomerase | 1 | 2010 | 153 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 253 | 0.020 |
Why?
|
| Chemokine CCL19 | 1 | 2009 | 6 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2009 | 14 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 264 | 0.020 |
Why?
|
| Netilmicin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2009 | 17 | 0.020 |
Why?
|
| Penicillin G | 1 | 1989 | 19 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 1989 | 12 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 404 | 0.020 |
Why?
|
| Lac Operon | 2 | 2001 | 90 | 0.020 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 18 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 1989 | 30 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 1282 | 0.020 |
Why?
|
| Alleles | 2 | 2004 | 1610 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 337 | 0.020 |
Why?
|
| Tartrates | 1 | 1988 | 2 | 0.020 |
Why?
|
| RNA, Neoplasm | 4 | 1991 | 126 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1988 | 13 | 0.020 |
Why?
|
| National Health Programs | 1 | 2008 | 20 | 0.020 |
Why?
|
| Cricetinae | 1 | 1989 | 365 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2008 | 42 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 395 | 0.020 |
Why?
|
| Thymidine | 1 | 1988 | 52 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1988 | 54 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 386 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 352 | 0.020 |
Why?
|
| Preoperative Care | 2 | 1989 | 355 | 0.020 |
Why?
|
| Terminal Repeat Sequences | 1 | 2008 | 19 | 0.020 |
Why?
|
| Drug Synergism | 4 | 1989 | 232 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2008 | 59 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1989 | 207 | 0.020 |
Why?
|
| Luciferases | 1 | 2008 | 125 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 81 | 0.020 |
Why?
|
| Daunorubicin | 2 | 2001 | 25 | 0.020 |
Why?
|
| Response Elements | 1 | 2008 | 99 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 2000 | 207 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 348 | 0.020 |
Why?
|
| Pokeweed Mitogens | 2 | 1987 | 2 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1989 | 166 | 0.020 |
Why?
|
| Cell Cycle | 2 | 2001 | 587 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 535 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cytotoxins | 1 | 1987 | 23 | 0.020 |
Why?
|
| Brain | 2 | 2001 | 3051 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 132 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1987 | 56 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1989 | 288 | 0.020 |
Why?
|
| Feedback | 1 | 1988 | 148 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2006 | 11 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1998 | 241 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 89 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2001 | 511 | 0.020 |
Why?
|
| Carrier State | 2 | 2002 | 80 | 0.020 |
Why?
|
| Cystitis | 1 | 1987 | 48 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 1207 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 2 | 1998 | 17 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 1986 | 27 | 0.020 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1986 | 29 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 1986 | 57 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 106 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1127 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 123 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 363 | 0.020 |
Why?
|
| Biological Products | 1 | 1988 | 138 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1990 | 1382 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1986 | 205 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1562 | 0.010 |
Why?
|
| Receptors, OX40 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Dopamine | 1 | 1987 | 246 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1989 | 588 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 1986 | 220 | 0.010 |
Why?
|
| Chromium | 1 | 2005 | 7 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3565 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 35 | 0.010 |
Why?
|
| Polylysine | 1 | 2004 | 11 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2004 | 31 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 55 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 125 | 0.010 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2004 | 6 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 244 | 0.010 |
Why?
|
| Methotrexate | 1 | 2006 | 317 | 0.010 |
Why?
|
| Serotyping | 1 | 2004 | 172 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2004 | 74 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1984 | 79 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 51 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 31 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2814 | 0.010 |
Why?
|
| Leukemia Virus, Gibbon Ape | 1 | 2003 | 1 | 0.010 |
Why?
|
| Random Allocation | 3 | 1989 | 419 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2004 | 213 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1987 | 492 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 327 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 14 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3720 | 0.010 |
Why?
|
| Culture Media | 1 | 1983 | 173 | 0.010 |
Why?
|
| Vero Cells | 1 | 2003 | 112 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2003 | 33 | 0.010 |
Why?
|
| HLA-DP beta-Chains | 1 | 2002 | 10 | 0.010 |
Why?
|
| Tetanus | 1 | 1983 | 22 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 32 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 181 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 18 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 104 | 0.010 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 1 | 2002 | 5 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 226 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2002 | 52 | 0.010 |
Why?
|
| Etoposide | 2 | 1992 | 109 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 13 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 477 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2002 | 29 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 82 | 0.010 |
Why?
|
| Attachment Sites, Microbiological | 1 | 2001 | 7 | 0.010 |
Why?
|
| Pediatrics | 1 | 2011 | 1205 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 234 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2003 | 231 | 0.010 |
Why?
|
| HLA-A11 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
| DNA Probes | 2 | 1992 | 120 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 123 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 96 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 380 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 572 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2001 | 359 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 59 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 622 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1999 | 6 | 0.010 |
Why?
|
| Janus Kinase 3 | 1 | 1999 | 14 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 139 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2000 | 80 | 0.010 |
Why?
|
| Alu Elements | 1 | 2000 | 67 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 517 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 586 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 604 | 0.010 |
Why?
|
| Public Policy | 1 | 1999 | 54 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1999 | 45 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 1999 | 11 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 132 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 1998 | 22 | 0.010 |
Why?
|
| Microinjections | 1 | 1998 | 41 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2000 | 418 | 0.010 |
Why?
|
| Rituximab | 1 | 2000 | 166 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 676 | 0.010 |
Why?
|
| RNA, Transfer, Amino Acyl | 1 | 1998 | 5 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1998 | 10 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1999 | 307 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1999 | 153 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1998 | 69 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1998 | 43 | 0.010 |
Why?
|
| HIV | 1 | 1999 | 171 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 308 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 361 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 348 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 14 | 0.010 |
Why?
|
| Resource Allocation | 1 | 1996 | 52 | 0.010 |
Why?
|
| Schwann Cells | 1 | 1996 | 56 | 0.010 |
Why?
|
| Health Care Rationing | 1 | 1996 | 59 | 0.010 |
Why?
|
| Genetic Research | 1 | 1996 | 55 | 0.010 |
Why?
|
| Long-Term Potentiation | 1 | 1996 | 106 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1998 | 511 | 0.010 |
Why?
|
| Drug Industry | 1 | 1995 | 48 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1998 | 300 | 0.010 |
Why?
|
| Lung | 2 | 1994 | 1523 | 0.010 |
Why?
|
| Rabbits | 2 | 1987 | 626 | 0.010 |
Why?
|
| Internationality | 1 | 1996 | 128 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 3331 | 0.010 |
Why?
|
| Binding Sites | 1 | 1998 | 1187 | 0.010 |
Why?
|
| Universities | 1 | 1995 | 120 | 0.010 |
Why?
|
| Laboratories | 1 | 1995 | 80 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1995 | 79 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 1995 | 75 | 0.010 |
Why?
|
| Mycoses | 1 | 1996 | 112 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 91 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2001 | 1774 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 540 | 0.010 |
Why?
|
| Self Concept | 1 | 1995 | 158 | 0.010 |
Why?
|
| Autoradiography | 1 | 1994 | 65 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 1996 | 321 | 0.010 |
Why?
|
| Myelin Proteins | 1 | 1994 | 74 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 449 | 0.010 |
Why?
|
| Autopsy | 1 | 1993 | 113 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 882 | 0.010 |
Why?
|
| Plasma | 1 | 1993 | 102 | 0.010 |
Why?
|
| Survivors | 1 | 1995 | 347 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1993 | 251 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 561 | 0.010 |
Why?
|
| Amsacrine | 1 | 1992 | 5 | 0.010 |
Why?
|
| 2-Chloroadenosine | 1 | 1992 | 5 | 0.010 |
Why?
|
| Cladribine | 1 | 1992 | 9 | 0.010 |
Why?
|
| Deoxyadenosines | 1 | 1992 | 9 | 0.010 |
Why?
|
| Azacitidine | 1 | 1992 | 51 | 0.010 |
Why?
|
| Cytarabine | 1 | 1992 | 99 | 0.010 |
Why?
|
| Neprilysin | 1 | 1991 | 19 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 962 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1992 | 134 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1990 | 24 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1990 | 59 | 0.010 |
Why?
|
| Transcription Factor TFIID | 1 | 1990 | 17 | 0.010 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 64 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1990 | 47 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1990 | 243 | 0.000 |
Why?
|
| Cognition | 1 | 1995 | 806 | 0.000 |
Why?
|
| Azlocillin | 1 | 1989 | 1 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 297 | 0.000 |
Why?
|
| Piperacillin | 1 | 1989 | 14 | 0.000 |
Why?
|
| United Kingdom | 1 | 1990 | 235 | 0.000 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1989 | 3 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 283 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1989 | 49 | 0.000 |
Why?
|
| Herpes Zoster | 1 | 1989 | 25 | 0.000 |
Why?
|
| beta-Lactams | 1 | 1989 | 57 | 0.000 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 1988 | 1 | 0.000 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1990 | 270 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1988 | 136 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1988 | 141 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 298 | 0.000 |
Why?
|
| Rauscher Virus | 1 | 1968 | 2 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1990 | 769 | 0.000 |
Why?
|
| Host vs Graft Reaction | 1 | 1988 | 1 | 0.000 |
Why?
|
| Immune Sera | 1 | 1968 | 84 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1990 | 396 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1988 | 215 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1988 | 153 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1988 | 111 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1989 | 192 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1986 | 27 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1989 | 514 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1987 | 46 | 0.000 |
Why?
|
| Ficoll | 1 | 1986 | 1 | 0.000 |
Why?
|
| Metrizoic Acid | 1 | 1986 | 2 | 0.000 |
Why?
|
| Hematuria | 1 | 1987 | 49 | 0.000 |
Why?
|
| Adenylyl Cyclases | 1 | 1987 | 60 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1996 | 3597 | 0.000 |
Why?
|
| Coombs Test | 1 | 1986 | 6 | 0.000 |
Why?
|
| Alkylation | 1 | 1986 | 10 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 1388 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1986 | 57 | 0.000 |
Why?
|
| Fenoldopam | 1 | 1986 | 5 | 0.000 |
Why?
|
| Antibody-Producing Cells | 1 | 1986 | 6 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1986 | 80 | 0.000 |
Why?
|
| Caudate Nucleus | 1 | 1986 | 36 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1989 | 823 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1986 | 156 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1986 | 126 | 0.000 |
Why?
|
| DNA Replication | 1 | 1987 | 346 | 0.000 |
Why?
|
| Bilirubin | 1 | 1986 | 124 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1989 | 1148 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1987 | 276 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1986 | 222 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 566 | 0.000 |
Why?
|
| Immunization, Secondary | 1 | 1986 | 114 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1602 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1990 | 962 | 0.000 |
Why?
|
| Myocardium | 1 | 1989 | 845 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1986 | 423 | 0.000 |
Why?
|
| Methods | 1 | 1968 | 121 | 0.000 |
Why?
|
| Haplorhini | 1 | 1968 | 107 | 0.000 |
Why?
|
| Kidney | 1 | 1968 | 1283 | 0.000 |
Why?
|